Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company developing FcRn-targeting monoclonal antibodies for IgG-mediated autoimmune diseases. The news flow around IMVT reflects its focus on advancing its lead asset IMVT-1402 and its first-generation antibody batoclimab through multiple clinical programs and financing events.
On this page, readers can follow company-issued updates such as quarterly and annual financial results, where Immunovant reports research and development spending, general and administrative expenses, net loss and cash position. These releases often include details on the status of potentially registrational trials of IMVT-1402 in Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis and Sjögren’s disease, as well as a proof-of-concept trial in cutaneous lupus erythematosus.
News items also cover clinical data readouts. Immunovant has announced topline results from a Phase 3 study of batoclimab in myasthenia gravis and initial results from a Phase 2b study in CIDP, highlighting correlations between deeper IgG reductions and improved clinical outcomes. Additional communications describe six‑month off‑treatment remission data from a batoclimab proof‑of‑concept study in uncontrolled Graves’ disease and the design of IMVT‑1402 trials informed by these findings.
Investors can also see coverage of corporate developments, including leadership transitions, changes in board composition and strategic alignment with controlling stockholder Roivant Sciences Ltd. Capital markets updates, such as the pricing of a common stock financing with anticipated gross proceeds of approximately $550 million, are reported through news releases as well.
For anyone tracking IMVT, this news feed provides company-sourced information on clinical milestones, financial reporting, governance changes and equity offerings related to Immunovant’s autoimmune disease pipeline.
Immunovant, a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced that CEO Pete Salzmann will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The chat is scheduled for September 14 at 4:00 PM Eastern Time. Interested parties can access the presentation via a webcast on the company’s website. Immunovant is developing innovative therapies, including the investigational compound batoclimab, a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn).
Immunovant (Nasdaq: IMVT) plans to initiate a pivotal Phase 2b trial for batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in late 2022, with expected results from an open-label period by early 2024. A Phase 2 trial for Graves’ Disease is set for early 2023, with results anticipated later that year. The company expects a steady stream of clinical data every six months from late 2023 through early 2025, encompassing multiple indications. Immunovant continues to pursue batoclimab's development across five autoimmune conditions.
Immunovant, Inc. (Nasdaq: IMVT) has announced plans to advance the development of batoclimab for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Graves' Disease. A pivotal Phase 2b trial for CIDP is set to begin in late 2022, with initial results from an open-label period expected in early 2024. A Phase 2 trial for Graves’ Disease will start in early 2023, with results anticipated in late 2023. Immunovant aims for regular clinical data readouts every six months from late 2023 to early 2025, covering multiple indications, including Myasthenia Gravis and Thyroid Eye Disease.
Immunovant, a clinical-stage biopharmaceutical company focused on autoimmune diseases, will host a webcast on September 7, 2022 at 8:00 AM ET to announce two new indications for batoclimab. The event will feature remarks from company management and external key opinion leaders, followed by a live Q&A session. Interested participants can register for the webcast here. An archived recording will be available on the company's website afterward.
Immunovant, focused on autoimmune diseases, reported its financial results for Q1 fiscal 2022, ending June 30, 2022. Key updates include the initiation of a pivotal trial for batoclimab in Myasthenia Gravis, with top-line data expected in 2024. Two pivotal trials for Thyroid Eye Disease are planned for the second half of 2022. Financially, the company incurred $31 million in cash payments due to clinical trial costs. The cash balance stood at $427 million, anticipated to last into 2025. Net loss was $40.4 million, reflecting increased R&D and G&A expenses.
Immunovant (Nasdaq: IMVT) plans to start two Phase 3 trials for batoclimab in thyroid eye disease (TED) by late 2022, with top-line results expected in the first half of 2025. The U.S. TED patient market is estimated at 8,000-18,000. The company has a cash balance of $494 million as of March 31, 2022, ensuring operational funding into 2025. R&D expenses surged to $32 million in Q4 2022, while FY 2022 losses grew to $156.7 million. The firm is also set to initiate a Phase 3 trial in myasthenia gravis (MG) by June 2022.
Immunovant, Inc. (Nasdaq: IMVT) will release its fourth quarter and full-year 2022 financial results on June 8, 2022, before U.S. market open. The company will also host a conference call and webcast at 8:00 AM ET the same day, featuring a question-and-answer session for investors. Immunovant focuses on therapies for autoimmune diseases, particularly its investigational compound, batoclimab, a monoclonal antibody targeting the neonatal Fc receptor (FcRn). This information can be accessed via their investor relations website.
Immunovant (Nasdaq: IMVT) announced on May 23, 2022, that CEO Pete Salzmann will participate in a fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022.
The chat is scheduled for May 25 at 12:30 pm ET and will be available via webcast on the company's Investor Relations page at www.immunovant.com.
Immunovant focuses on developing innovative therapies for autoimmune diseases, notably their investigational compound, batoclimab.
Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will participate in a fireside chat at the UBS Global Healthcare Conference from May 23-25, 2022.
The chat is scheduled for May 23 at 1:15 PM ET and will be accessible via webcast on the company's website. Immunovant is dedicated to developing therapies for autoimmune diseases, focusing on its investigational compound, batoclimab, a fully human monoclonal antibody targeting the neonatal Fc receptor.
Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann, M.D., will participate in a fireside chat during the LifeSci Partners’ virtual Immunology and Inflammation Symposium on May 10-11, 2022. The chat is scheduled for 12:00 PM Eastern Time on May 10. Interested parties can access the webcast through the Investor Relations section of the company's website at www.immunovant.com. Immunovant specializes in treating autoimmune diseases and is known for its innovative therapies, including the investigational compound batoclimab.